|Day Low/High||46.84 / 48.24|
|52 Wk Low/High||35.84 / 67.74|
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
Obamacare? Trumpcare? These stocks don't care.
Here's a rundown of four technical setups that are showing solid trading potential.
Investigational New Drug (IND) Submission Expected by Year End 2017
Here's how to rake in the profits off some potential big breakouts.
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.
Here are Tuesday's top research calls, including upgrades for Disney, Continental Resources and Agios Pharmaceuticals, and downgrades for Chipotle, Brinker International and JPMorgan Chase.
Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.
Announces Innovative $285 Million Follow-on Capital Pool for Special Opportunities
Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc.